Mycophenolat Mofetil Sandoz (Mycophenolate Mofetil)

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks the synthesis of guanosine nucleotides, a step essential for the proliferation of T‑ and B‑lymphocytes, thereby reducing immune responses.

The dosage of Mycophenolat Mofetil Sandoz is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and concomitant therapies. Typical regimens range from 1 to 3 g per day divided into two doses, but the exact schedule must be set by a qualified health professional.

Mycophenolate mofetil is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended while breastfeeding, as the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azathioprine or cyclophosphamide, mycophenolate mofetil offers a more selective inhibition of lymphocyte proliferation and often a better tolerability profile. However, choice of therapy depends on the clinical scenario, organ transplanted, patient comorbidities and physician experience.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze the product.

Mycophenolat Mofetil is taken orally as a tablet, with or without food, according to the dose prescribed by the clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious adverse events include life‑threatening infections, progressive multifocal leukoencephalopathy (PML), severe bone‑marrow suppression leading to leukopenia or anemia, and rare cases of malignancy such as lymphomas. Patients should be monitored closely for signs of infection, blood count changes and organ dysfunction.

Mycophenolat Mofetil is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or any component of the formulation, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal impairment or existing bone‑marrow disorders.